US7998128B2 - Active delivery and flow redirection: novel devices and method of delivery of materials to patients - Google Patents

Active delivery and flow redirection: novel devices and method of delivery of materials to patients Download PDF

Info

Publication number
US7998128B2
US7998128B2 US11/434,080 US43408006A US7998128B2 US 7998128 B2 US7998128 B2 US 7998128B2 US 43408006 A US43408006 A US 43408006A US 7998128 B2 US7998128 B2 US 7998128B2
Authority
US
United States
Prior art keywords
catheter
pia
delivery
seal
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related, expires
Application number
US11/434,080
Other languages
English (en)
Other versions
US20070276340A1 (en
Inventor
David Poston
Raghu Raghavan
Martin L. Brady
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Therataxis LLC
Original Assignee
Therataxis LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therataxis LLC filed Critical Therataxis LLC
Priority to US11/434,080 priority Critical patent/US7998128B2/en
Assigned to THERATAXIS, LLC reassignment THERATAXIS, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BRADY, MARTIN L., RAGHAVAN, RAGHU, POSTON, DAVID
Priority to PCT/US2007/011634 priority patent/WO2007133776A2/fr
Priority to US12/226,579 priority patent/US20100030102A1/en
Publication of US20070276340A1 publication Critical patent/US20070276340A1/en
Application granted granted Critical
Publication of US7998128B2 publication Critical patent/US7998128B2/en
Expired - Fee Related legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0021—Catheters; Hollow probes characterised by the form of the tubing
    • A61M25/0023—Catheters; Hollow probes characterised by the form of the tubing by the form of the lumen, e.g. cross-section, variable diameter
    • A61M25/0026—Multi-lumen catheters with stationary elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/34—Trocars; Puncturing needles
    • A61B17/3401—Puncturing needles for the peridural or subarachnoid space or the plexus, e.g. for anaesthesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0021—Catheters; Hollow probes characterised by the form of the tubing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
    • A61M25/0068—Static characteristics of the catheter tip, e.g. shape, atraumatic tip, curved tip or tip structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
    • A61M25/0068—Static characteristics of the catheter tip, e.g. shape, atraumatic tip, curved tip or tip structure
    • A61M25/0069—Tip not integral with tube
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/34—Trocars; Puncturing needles
    • A61B17/3417—Details of tips or shafts, e.g. grooves, expandable, bendable; Multiple coaxial sliding cannulas, e.g. for dilating
    • A61B17/3421—Cannulas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/34—Trocars; Puncturing needles
    • A61B17/3417—Details of tips or shafts, e.g. grooves, expandable, bendable; Multiple coaxial sliding cannulas, e.g. for dilating
    • A61B2017/3419—Sealing means between cannula and body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2002/826—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents more than one stent being applied sequentially
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0021—Catheters; Hollow probes characterised by the form of the tubing
    • A61M2025/0042—Microcatheters, cannula or the like having outside diameters around 1 mm or less
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
    • A61M25/0082—Catheter tip comprising a tool
    • A61M2025/0096—Catheter tip comprising a tool being laterally outward extensions or tools, e.g. hooks or fibres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
    • A61M25/06—Body-piercing guide needles or the like
    • A61M25/0662—Guide tubes
    • A61M2025/0681—Systems with catheter and outer tubing, e.g. sheath, sleeve or guide tube
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
    • A61M25/0074—Dynamic characteristics of the catheter tip, e.g. openable, closable, expandable or deformable

Definitions

  • the present invention relates to the field of medical procedures, particularly invasive medical procedures, and more particularly invasive medical procedures to the brain.
  • the brain is found inside the bony covering called the cranium.
  • the cranium protects the brain from injury. Together, the cranium and bones that protect our face are called the skull. Meninges are three layers of tissue that cover and protect the brain and spinal cord. From the outermost layer inward they are: the dura mater, arachnoid and pia mater.
  • the dura mater is made up of two layers of whitish, inelastic (not stretchy) film or membrane. The outer layer is called the periosteum.
  • An inner layer, the dura lines the inside of the entire skull and creates little folds or compartments in which parts of the brain are neatly protected and secured. There are two special folds of the dura in the brain, the falx and the tentorium. The falx separates the right and left half of the brain and the tentorium separates the upper and lower parts of the brain.
  • the second layer of the meninges is the arachnoid.
  • This membrane is thin and delicate and covers the entire brain.
  • the arachnoid is made up of delicate, elastic tissue and blood vessels of different sizes.
  • the layer of meninges closest to the surface of the brain is called the pia mater.
  • the pia mater has many blood vessels that reach deep into the surface of the brain.
  • the pia which covers the entire surface of the brain, follows the folds of the brain.
  • the major arteries supplying the brain provide the pia with its blood vessels.
  • the space that separates the arachnoid and the pia is called the subarachnoid space.
  • a clear fluid may often lie within the interface between the pia and the next adjacent layer.
  • Cerebrospinal fluid also known as CSF
  • CSF Cerebrospinal fluid
  • This fluid circulates through channels around the spinal cord and brain, constantly being absorbed and replenished. It is within hollow channels in the brain, called ventricles, where the fluid is produced. A specialized structure within each ventricle, called the choroid plexus, is responsible for the majority of CSF production.
  • the brain normally maintains a balance between the amount of cerebrospinal fluid that is absorbed and the amount that is produced. Often, disruptions in the system occur.
  • the pia has been generally treated as a barrier or annoyance in accessing or treating areas of the brain during surgery and procedures have been generally performed without any attempt to use the presence of the pia as a benefit. See for example, the procedures in Journal of Neuroscience, Volume 16, Number 18, Issue of Sep. 15, 1996 pp. 5864-5869 ; Interaction of Perirhinal Cortex with the Fornix - Fimbria: Memory for Objects and ‘Object - in - Place’ Memory , David Gaffan and Amanda Parker.
  • U.S. Pat. Nos. 6,663,857; 6,506,378; 5,762,926 and 5,082,670 describe graft procedures wherein a graft may be placed in a ventricle, e.g. a cerebral ventricle or subdurally, i.e. on the surface of the host brain where it is separated from the host brain parenchyma by the intervening pia mater or arachnoid and pia mater. Grafting to the ventricle may be accomplished by injection of the producer cells or by growing the cells in a substrate such as 30% collagen to form a plug of solid tissue which may then be implanted into the ventricle to prevent dislocation of the graft.
  • a ventricle e.g. a cerebral ventricle or subdurally, i.e. on the surface of the host brain where it is separated from the host brain parenchyma by the intervening pia mater or arachnoid and pia mater.
  • Grafting to the ventricle may be accomplished
  • the cells may be injected around the surface of the brain after making a slit in the dura. Injections into selected regions of the host brain may be made by drilling a hole and piercing the dura to permit the needle of a microsyringe to be inserted.
  • the microsyringe is preferably mounted in a stereotaxic frame and three dimensional stereotaxic coordinates are selected for placing the needle into the desired location of the brain.
  • U.S. Pat. No. 5,843,048 describes syringe tip designs for use in epidural applications.
  • the designs include straight epidural needles employed in the former procedure do not require the passage of a catheter. These typically have a straight distal end and a gauge size on the order of 21-22 gauge (iso-9626); while those of the latter type, through which a catheter is introduced, of necessity are somewhat larger, having a gauge size typically on the order of 17-18 gauge (iso-9626).
  • the needles of the latter type used for introducing a catheter into the epidural space, are described as possessing a curved tip so that the distal end of the catheter can curve upward for proper placement within the epidural space rather than perpendicularly abutting the dura mater, the delicate membrane lying over the arachnoid and pia mater covering the spinal cord.
  • U.S. Pat. No. 6,626,902 (Kucharczyk et al.) describes new hardware for delivery of drugs intraparenchymally and to regions of the brain in particular comprising a multi-lumen, multi-functional catheter system.
  • the system comprises a plurality of axial lumens, at least one lumen supporting material delivery of primary treatment chemistry to a point of release and a second lumen having a component supporting a functionality electrostatically near the point of release other than material delivery and material removal wherein at least one biological or physiological measuring device is present within at least one lumen in which information from said at least one biological or physiological measuring device is connected to a host computer and said information is received by said host computer, wherein the component provides information other than information from said at least one biological or physiological measuring device and the component is connected to a host computer and said information is received by said host computer.
  • U.S. Pat. No. 6,537,232 (Kucharczyk et al.) describes a device and method for monitoring intracranial pressure during magnetic resonance (MR) image-guided neurosurgical procedures, such as intracranial drug delivery procedures, wherein an MR-compatible microsensor pressure transducer coupled to a pressure sensing diaphragm located a) at the tip, b) on a lateral side, and/or c) in multiple locations of an MR-compatible catheter is inserted into a lateral cerebral ventricle, cerebral cistern, subarachnoid space, subdural or extradural spaces, venous sinuses, or intraparenchymal tissue locations under MR imaging guidance, and is used to record intracranial pressures over hours to days in patients undergoing diagnostic or therapeutic neurologic interventions.
  • MR magnetic resonance
  • the standard current procedure for drug treatment of various focal neurological disorders, neurovascular diseases, and neurodegenerative processes requires neurosurgeons or interventional neuroradiologists to deliver drug agents by catheters or other tubular devices directed into the cerebrovascular or cerebroventricular circulation, or by direct injection of the drug agent, or cells which biosynthesize the drug agent, into targeted intracranial tissue locations.
  • the blood-brain barrier and blood-cerebrospinal fluid barrier almost entirely exclude large molecules like proteins, and control entry of smaller molecules. Small molecules ( ⁇ 200 Daltons) which are lipid-soluble, not bound to plasma proteins, and minimally ionized, such as nicotine, ethanol, and some chemotherapeutic agents, readily enter the brain. Water soluble molecules cross the barriers poorly or not at all.
  • a drug into a ventricle bypasses the blood-brain barrier, and allows for a wide distribution of the drug in the brain ventricles, cisterns, and spaces due to the normal flow pathways of cerebrospinal fluid in the brain.
  • many therapeutic drug agents particularly large-molecular weight hydrophobic drugs, fail to reach their target receptors in brain parenchyma because of metabolic inactivation and inability to diffuse into brain tissues, which may be up to 18 mm from a cerebrospinal fluid surface.
  • Magnetic resonance imaging will likely play an increasingly important role in optimizing drug treatment of neurological disorders.
  • One type of MR unit designed for image-guided therapy is arranged in a “double-donut” configuration, in which the imaging coil is split axially into two components. Imaging studies are performed with this system with the surgeon standing in the axial gap of the magnet and carrying out procedures on the patient.
  • a second type of high-speed MR imaging system combines high-resolution MR imaging with conventional X-ray fluoroscopy and digital subtraction angiography (DSA) capability in a single hybrid unit. Both of these new generations of MR scanners provide frequently updated images of the anatomical structures of interest. This real-time imaging capability makes it possible to use high-speed MR imaging to direct the movement of catheters and other drug delivery vehicles to specific tissue locations, and thereby observe the effects of specific interventional procedures.
  • U.S. Pat. No. 5,571,089 to Crocker et al. and U.S. Pat. No. 5,514,092 to Forman et al. disclose endovascular drug delivery and dilatation drug delivery catheters which can simultaneously dilate and deliver medication to a vascular site of stenosis.
  • U.S. Pat. No. 5,171,217 to March describes the delivery of several specific compounds through direct injection of microcapsules or microparticles using multiple-lumen catheters, such as disclosed by Wolinsky in U.S. Pat. No. 4,824,436.
  • Unger et al. discloses a method of administering drugs using gas-filled liposomes comprising a therapeutic compound, and inducing the rupture of the liposomes with ultrasound energy.
  • U.S. Pat. No. 5,017,566 to Bodor discloses redox chemical systems for brain-targeted drug delivery of various hormones, neurotransmitters, and drugs through the intact blood-brain barrier.
  • U.S. Pat. No. 5,226,902 to Bae et al. and U.S. Pat. No. 4,973,304 to Graham et al. disclose drug delivery devices, in which biologically active materials present within a reversibly permeable hydrogel compartment can be delivered into tissues by various endogenous and exogenous stimuli.
  • U.S. Pat. No. 5,167,625 to Jacobsen et al. discloses an implantable drug delivery system utilizing multiple drug compartments which are activated by an electrical circuit.
  • U.S. Pat. No. 4,941,874 to Sandow et al. discloses a device for the injection of implants, including drug implants that may used in the treatment of diseases.
  • U.S. Pat. Nos. 4,892,538, 4,892,538, 5,106,627, 5,487,739 and 5,607,418 to Aebischer et al. disclose implantable drug therapy systems for local delivery of drugs, cells and neurotransmitters into the brain, spinal cord, and other tissues using delivery devices with a semipermeable membrane disposed at the distal end.
  • the coating can incorporate natural or synthetic materials that act as antibiotics, anticancer agents, and antithrombotics, according to the issued patent.
  • U.S. Pat. No. 5,573,668 to Grosh et al. discloses a microporous drug delivery membrane based on an extremely thin hydrophilic shell.
  • U.S. Pat. No. 5,569,197 to Helmus et al. discloses a drug device guidewire formed as a hollow tube suitable for drug infusion in thrombolytic and other intraluminal procedures.
  • the assembly ensures delivery of the drug to the selected site by providing a barrier which prevents “backflow” or leakage of the drug.
  • the assembly includes a guide catheter having an inflatable balloon which is able to seal or occlude the tract created by the insertion of the guide catheter into the brain.
  • the guide catheter further includes a passageway which receives a delivery catheter through which the drug is administered to the selected site in the brain.
  • a procedure or method allows for a unique positioning of materials and methods of drug delivery within or adjacent to tissues of a patient and especially within the skull and to regions of the brain.
  • the new methods may be performed both for treatments and for evaluating the performance of a device or treatment for the delivery of materials in infusion delivery, perfusion delivery or catheter delivery of materials for diagnostic or treatment purposes.
  • Observable material e.g., material observable by invasive or non-invasive visual, MRI, PET, fluoroscopy, fiber optic or other methods
  • the movement characteristics e.g., direction of material movement, absorption rate, persistence or dwell time of the material, and movement rate
  • a delivery scheme is devised based upon the observed characteristics.
  • An active delivery mode is a new format of material delivery wherein a liquid to be administered (for diagnostic or treatment functionality) is provided, preferably in the form of a discrete mass, such as a bolus, directly between two opposed surfaces of a body element (e.g., especially the pia and the cortex) so that the discrete mass remains at least intact for a period sufficient to enable detection and observation.
  • a liquid to be administered for diagnostic or treatment functionality
  • the liquid delivery may be into that fluid, using the two enclosing surfaces as barriers against undesired movement of the delivered material, and assuring maximum local effect where desired.
  • the liquid material will be observed undergoing both flow between the layers and absorption into at least one of the opposed layers.
  • the system may also be practiced with an implantable format, where either a passive (diffusion or timed release) or active (e.g., pump) delivery from an implanted element (e.g., at least a patch, tube, release pack, pump or microcatheter) being positioned between the opposed surfaces in the desired target location in the patient.
  • a passive (diffusion or timed release) or active (e.g., pump) delivery from an implanted element e.g., at least a patch, tube, release pack, pump or microcatheter
  • the technique can be used to determine appropriate delivery locations, delivery rates and delivery modes.
  • the observational technique can thus be used to assist in specific treatment planning and assist in the improvement of device design by observing how catheter design variations affect the quality of material delivery.
  • the format of an observational approach for defining proposed delivery methodologies such as those disclosed in U.S. Pat. No. 6,749,833 could also be practiced.
  • One method of delivery according to techniques and protocols described herein is the delivery between natural boundaries within a patient in a manner such that the material delivered persists in the region, zone, volume, space or location for sufficient time (without normal mass transfer events in the delivery site removing the material) for the treatment, diagnosis, observation or other procedure to take place while sufficient materials remains in the delivery site.
  • Specially designed devices may assist in maintaining an appropriate or necessary concentration at the delivery site by preventing or educing back flow along the exterior sides of the delivery device.
  • FIG. 1 shows a schematic of an assembled twin-stent catheter in pre-insertion mode.
  • FIG. 2 shows the component parts of a twin-stent catheter.
  • FIG. 3 shows the distal tip of the twin-stent catheter in pre-insertion mode.
  • FIG. 4 shows a schematic of the twin-stent catheter in initial position piercing the pia.
  • FIG. 5 shows a drawing of the contracted twin-stent catheter gripping the pia.
  • FIG. 6 shows leakage out of the pia when a conventional catheter is inserted into cortex
  • FIG. 7 illustrates the claim of FIG. 6 by showing staining of paper placed outside the pia
  • FIG. 8 shows spreading of dye underneath the pia upon using the twin-stent catheter, one of the embodiments of the current invention.
  • FIG. 9 illustrates the claim of FIG. 8 by showing that the paper placed outside the pia is now not stained.
  • FIG. 10 shows the overall construction of the parasol catheter
  • FIG. 11 shows the inner tube of the parasol catheter and how it accommodates the folded parasol
  • FIG. 12 shows an intermediate stage of operation of the parasol catheter showing the liquid between the opposed layers as described in the invention.
  • FIG. 13 shows the parasol catheter sealing the pia.
  • FIG. 14 shows a construction of the ventricle circulation catheter.
  • FIG. 15 shows a construction of the pressure-equalization catheter.
  • FIG. 16 shows a graphic representation of pressure-driven intraparenchymal infusion.
  • FIG. 17 is an overlay of recommended distances used during infusion delivery by catheter.
  • FIG. 18A shows a guideline for catheter insertion.
  • FIG. 18B shows a guideline for catheter insertion.
  • FIG. 18C shows a guideline for catheter insertion.
  • FIG. 18D shows a guideline for catheter insertion.
  • FIG. 18E shows a guideline for catheter insertion.
  • FIG. 18F shows a guideline for catheter insertion.
  • FIG. 18G shows a guideline for catheter insertion.
  • FIG. 18H shows a guideline for catheter insertion.
  • FIG. 19 shows four T1 weighted scans of the infusion of Gd-DTPA water solution.
  • FIG. 20A shows a first image of infusion of fluid into white matter producing changes that appear very similar to vasogenic edema.
  • FIG. 20B shows a second image of infusion of fluid into white matter producing changes that appear very similar to vasogenic edema.
  • FIG. 21 shows a third image of infusion of fluid into white matter producing changes that appear very similar to vasogenic edema.
  • FIG. 22 shows a graphic representation of distribution of high interstitial pressure adjacent material introduction.
  • FIG. 23 shows is an illustration of four sequential images of an infusion into a dog brain.
  • the technology disclosed herein includes methods, devices, apparatus, protocols, and systems for the delivery of materials into a living patient.
  • the material is delivered to a site where the material may persist for a time sufficient for allowing the observation, treatment, diagnosis, or the like to be performed without normal mass transfer events in the targeted sites removing the material or reducing the concentration of the material so rapidly or to such a significant degree as to prevent the effectiveness of the procedure.
  • Irreducible backflow is defined as the length (or other suitable dimension describing the flow along the surface of the catheter or device) of the fluid channel along the outer surface of the catheter that depends only on G, k and, of course, the geometry and parameters of the insertion (catheter dimensions, flow rate, viscosity). For usual cylindrical catheters of outer diameter of 1 millimeter at some clinical flow rates of less than a half milliliter per hour, these lengths are up to 3 centimeters.
  • the second concept considered is that of flow redirection.
  • the concept of “inertia” even in its customary non-technical meaning allows us to guess (and this assumption is supported by deeper understanding of fluid flow in deformable porous media) that if backflow is redirected to another very distinct direction (ideally involving an abrupt change of direction), the subsequent flow will not easily return to the original direction of backflow.
  • the pertinent fact is that once a sufficiently abrupt flow redirection is effected for a sufficient distance, the redirected streamlines will tend to persist and not return to their original configuration without further intervention. This effect may be reinforced by having tight seals on either side of an interface between two distinct layers, and also by the creation of channels due to the active response of tissue to pressure, another concept that is now explained.
  • the third concept which points to a second feature of the present technology is what is termed active tissue.
  • the tissue as already mentioned, is highly deformable, at least under shear. In fact, owing to the interlacing of blood vessels and other highly deformable reservoirs, it is also effectively quite compressible, even though its constituents, e.g. cells, are not. The net result is that when subjected to pressure-driven fluid flow, the tissue deforms, sometimes quite dramatically, sometimes more subtly, but often reliably enough to take advantage of this and not merely regard it as a nuisance.
  • Active tissue exploitation is a feature of the present technology and may work in more than one way, resulting in more than one embodiment. We describe several embodiments below.
  • a fourth feature of the present technology is the exploitation of irreducible backflow itself to spread infusate over regions otherwise not easily penetrable.
  • One method of delivery according to techniques and protocols described herein is the delivery between at least two distinct and different natural boundaries within a patient in a manner such that the material delivered persists in the region, zone, volume, space or location for sufficient time (without normal mass transfer events in the delivery site removing the material) for the treatment, diagnosis, observation or other procedure to take place while sufficient materials remains in the delivery site.
  • Natural boundaries include surfaces of tissues, organs, bones, ligaments, cartilage, and the like. By distinct and different it is meant that the natural boundaries may not necessarily be opposed surfaces of essentially the same material within a single component of an organ.
  • the space defined within a blood vessel has the essentially identical blood vessel walls opposing each other (in an essentially continuous manner) because of the structure of the vessel.
  • the space within sacs in the lungs, within ducts, in the volume of the stomach, within the cochlea, between muscles, and the like are not distinct and different.
  • the opposed tissue surfaces of the pia and cortex are non-limiting examples of distinct and different opposed surfaces.
  • the delivery may be through an implanted format, where there is active or passive delivery from an implanted system, with the physical delivery occurring between the opposed tissue surfaces.
  • the catheter is inserted 20 mm or more into the brain, this may pose relatively little problem.
  • the cortical structures which are typically thin layers near the surface of the brain, this could impose a stringent limit on the utility of the technique and affords a basis for indwelling device delivery.
  • the opposed surfaces have natural fluid reservoirs or mass between the distinct and different layers.
  • These reservoirs or masses should be mass transfer stable. That is, the materials within a given local volume, especially the targeted volume, should not be essentially 100% (e.g., no more than 80% and even no more than 70%) replaced within a 5 minute period (preferably less than 3, more preferably less than 2 minute, less than 1 minute, and less than 30 second) under normal environmental and functional events at that site.
  • a 5 minute period preferably less than 3, more preferably less than 2 minute, less than 1 minute, and less than 30 second
  • Ducts during normally active periods may replace fluids by mass transfer in longer time frames, but still within the 5 minute period identified above. Material is replaced over time in these regions, but usually by transparenchymal migration, perfusion, permeation and discharge, not by regular and relatively high percentage volume mass flow.
  • Specially designed devices may assist in maintaining an appropriate or necessary concentration at the delivery site by preventing or reducing back flow along the exterior sides of the delivery device.
  • Structures that tend to block or seal edges of the openings at the site of physical introduction of the delivery device, and especially around the sides or edges of the point of penetration of tissue by the delivery device are very desirable as this enhances the retention of the material at the delivery site and reduces unnatural (from the penetration of tissue) flow paths from the targeted site.
  • Such blocking or sealing structure may include inflatable surface functionality on the tube, gaskets, parasols, stents, tensioning surfaces that can cover or secure a region extending from the device surface over a sufficient area of the penetrated surface to assure an improved seal at the site of penetration.
  • the catheter may be a coaxial (two concentric lumens) catheter where the innermost catheter delivers the material and the outermost catheter wall is flexible or elastic and carries a fluid which may be pressurized to firm the seal between the catheter and the tissue, and even slightly bulge above and/or below the penetration site to prevent leakage.
  • Various aspects of the disclosed technology may be generally described as including a method for the provisioning and positioning of a flowable material into a region of a patient comprising: identifying a region of a patient to be viewed or treated; identifying a region wherein the region forms a potential volume between two opposed different and distinct surfaces; penetrating at least one of the two opposed different and distinct surfaces with a material delivery device; and providing material from the material delivery device into the potential volume to create a volume containing at least delivered material.
  • the method may have the volume as a mass transfer stable in that less than 80% by volume of delivered material is removed from the created volume by natural biological activity in less than 5 minutes.
  • the material delivery device may form an at least partial seal around a puncture formed by penetration of only one of the at least two opposed different and distinct surfaces.
  • the seal may be formed to cover a surface area extending circumferentially away from and around a diameter of the material delivery device.
  • the seal may be formed on both sides of the puncture relative to the opposed surface penetrated, or the seal may be formed on only one side of the puncture relative to the opposed surface penetrated.
  • a structure forming the seal may be distended, distorted, expanded, bent, flattened and/or inflated to assist in sealing the puncture.
  • a structure forming the seal may be flexible and distort to apply pressure over the puncture.
  • the two opposed surfaces may comprise the pia and the cortex.
  • a medical device for delivering material through tissue into a defined area of a patient may, by way of non-limiting examples, comprise: a material delivery element through which the material may flow out of a delivery end; the delivery end having an opening that can be inserted through a surface of the tissue; and a sealing system proximal to the delivery end that can extend away from the material delivery element along the surface of the tissue and apply pressure to the tissue after the material delivery element has been inserted through the surface of the tissue.
  • the material delivery device may be selected from the group consisting of a catheter and needle.
  • the sealing system may comprise at least two structural elements that are displaced from each other along the delivery end of the material delivery device. The two structural elements may be disposed at positions on opposite internal and external sides of a puncture in the surface of the tissue.
  • the sealing system may be inflatable. There may be a second seal formed against at least one surface in addition to the punctured surface, as where the punctured surface may be the pia and the second surface may be the dura.
  • the sealing system may comprise at least two components lying along a long axis of the material delivery device and within dimensions of a largest radius of the delivery end of the material delivery device in an at-rest position.
  • the at least two components of the sealing system may have their shape and size altered to assist in forming a seal.
  • a non-limiting example of this is where each of the at least two components has an initially tubular form and their exterior surfaces are coplanar with the material delivery device outer surfaces and the stents are essentially identical. Sealing procedures may cause the two components to alter their size and shape and consequently distort approximately equally.
  • the stents may each consist of a flexible tube, and during or after initial deployment, the final disposition of the stents is achieved by reducing the longitudinal space available to them where they are mounted on the catheter needle.
  • the deployment of the tube stents may be achieved by longitudinal compression achieved by movement of the catheter needle within the main body or outer casing of the catheter.
  • the position of the catheter body relevant to the distal tip and mass of the catheter needle may be adjusted automatically as the mechanism deploying the stents is activated, the two movements being linked.
  • sealing devices examples include sliding gaskets that may be moved along the exterior surface of the delivery device to abut the penetration site, parasols that may be deployed at the penetration site, and a design referred to herein and described in greater detail elsewhere as a twin-stent design.
  • CED Convection-Enhanced Delivery
  • FIG. 16 (which is not to scale) is a comparison of the rather limited spread one could expect from the diffusion of a macromolecule, compared to where it can be carried by fluid flow.
  • the diffusive spread will be often less than a millimeter in a day, not allowing for metabolic and other loss mechanisms.
  • the flow of a fluid co-injected with a drug can however carry such molecules far farther, and in certain idealized scenarios fill the intervening region with a full concentration of drug per unit of available volume. Diffusive spread results in exponentially decreasing concentrations away from a source.
  • the delivery device In most procedures for intraparenchymal infusion or injection, the delivery device is stereotactically guided to its intra-cranial target through a burr hole. For slow infusion processes, (typically in humans of rather less than 0.3 milliliters per hour) the catheter might be left indwelling for several days. Conventional MR/CT imaging studies are typically used pre-operatively to estimate the optimal insertion trajectory. However, the final operative details of the implantation procedure are usually specific to the design of the delivery device, the rate at which the infusion or injection is to occur, and the number of devices that must be inserted and/or passes that must be made to obtain adequate therapeutic coverage of the targeted volume. Infusion methodologies for both framed and frameless stereotaxis have been developed, with forms of the latter optimized for use in the interventional MR setting.
  • Problems that can potentially occur during any kind of intraparenchymal infusion or direct injection approach include backflow along the catheter or cannula insertion track, suction-displacement or reflux of the infused agent or injected cells along the withdrawal track during removal of the catheter or cannula, and cyst formation and other neurosurgical complications.
  • Backflow can result in spread of the agent into regions of the brain where it is not intended and, possibly, in diminution of the dose otherwise needed within the target tissues. The same holds for reflux during withdrawal.
  • the problem could be particularly acute in cortical infusions, where backflow of the agent along the insertion track and into the subarachnoid space could occur, with subsequent widespread distribution of the agent by the circulating cerebrospinal fluid.
  • the inventor is developing a model of the mechanics of the backflow process, and in it the backflow distance (for a fixed rate of fluid delivery through the catheter) varies as the four-fifths power of the catheter radius.
  • the backflow distance for a fixed rate of fluid delivery through the catheter
  • the backflow distance for a fixed rate of fluid delivery through the catheter
  • the backflow distance for a fixed rate of fluid delivery through the catheter
  • the backflow distance for a fixed rate of fluid delivery through the catheter
  • the material to be dispensed from the implanted system may also be represented as a sphere around the catheter tip representing a recommended distance to fluid filled cavities.
  • Distance Line The depth line of delivery may also be represented on a map of the target area by a sphere of 2 cm diameter around the catheter tip representing the recommended minimal distance between catheters.
  • implantable patches that can be inserted into patients that are commercially available, but none of these have been used to provide the administration or delivery of medically applicable materials between the opposed surfaces to control the rate and location of delivery.
  • a patch type material to be delivered, as by putting the active ingredients in a mass that will persist for a period of time that is desired, and then harmlessly dissolve.
  • the mass could be as rapid dissolving and harmless as mannitol, rabbitol or other sugar-type material, or could be more persistent, yet harmless with natural polymers such as gelatin or gums and resins (amylase).
  • soluble synthetic polymers such as polyvinyl alcohol
  • carrier media should be carefully considered for their toxicity and undesirable level of persistence.
  • the outer circle in FIG. 17 shows the Distance Line and the inner circle in combination with the cylinder along the trajectory the Depth line.
  • the following described graphics illustrate in more detail the guidelines. The basic point from all of these Figures is that such restrictions are completely out of the question for small animal brains.
  • FIG. 18B shows a poor placement that is the result of the following process.
  • the catheter was inserted too far and encountered a fluid reservoir (e.g., ventricle, resection cavity). It was then withdrawn back into the tissue proper. However, this will leave an unhealed track and any infusion is likely to follow it into the reservoir. Equally, traversing an “internal” sulcus like the Sylvian fissure will also compromise an infusion, as shown in FIG. 18E .
  • a fluid reservoir e.g., ventricle, resection cavity
  • FIG. 19 illustrates the leakage of infusate into the subarachnoid space via backflow up the catheter.
  • a 0.85 mm diameter catheter was inserted through a burr hole into in-vivo pig brain to a depth of 14 mm from the cortical surface.
  • 1:200 Gd-DTPA:water solution was infused at 5 microliters per minute.
  • FIG. 19 shows infusion of 1:200 Gd-DTPA:water solution with four T1-weighted 3D SPGR slices, at a 3 mm separation.
  • the infusion catheter is visible in the first slice (left). Subsequent slices reveal leakage and spread of the infusate into the subarachnoid space.
  • FIG. 21 shows the distribution of SPECT marker roughly matching the area of edema.
  • the extent of the edema appears to match the extent of the infused fluid closely, according to infused gadolinium and SPECT markers.
  • the level of the infusion-related edema for a 4.5 ⁇ L/min infusion is often greater than that observed of tumor-induced vasogenic edema.
  • the T2 levels near the infusion reach values very near that of fluid-filled cavities and ventricles.
  • the infusate itself may have a higher T2 than that of CSF, so it is difficult to make a quantitative assessment from the T2 weighted values as to whether the infusion-induced edema has a water fraction higher than that of the average vasogenic edema.
  • T2 weighted values displayed in FIGS. 20 a , 20 b and 21 .
  • Direct targeting of the cortical grey matter for sub-pial infusion is complicated by the tendency of the infusate to backflow along the catheter shaft for several centimeters, depending upon flow rate, catheter radius, and properties of the tissue.
  • the infusate tends to follow the low-resistance path out through the pia and into the subarachnoid space.
  • the fluid distributes widely through the subarachnoid, but for most infused compounds, the pia acts as a barrier preventing the compound from entering the cortex.
  • White matter infusions can sidestep this problem by placing the catheter deep within tissue, far from the brain surface, an option not available for cortical infusion.
  • FIGS. 20 a, b and 21 illustrate this.
  • a standard catheter when Infusions into tumors present their own special problems. Active tumors present a variety of additional barriers to drug delivery
  • FIG. 23 This is illustrated in the four images of FIG. 23 .
  • the magnetic resonance images taken of an infusion into a dog show rather clearly the barrier presented by an active tumor.
  • the pia offers a membrane that can be used to hold materials, especially materials with a molecular weight above 400, above 500, above 1000 and the like, and especially markers and medication against the cortical surface using an appropriate method of delivery described herein, especially using specifically designed catheter elements.
  • the structure of the catheter element can be observed and enhanced under observation, here by direct (including MR, X-ray, fluoroscopy, CT etc.) visual observation.
  • a marker, dye or pigment may be used and the material observed directly (e.g., with optical fibers) or by medical visualization techniques (e.g., MR, ultrasound, fluoroscopy, PET, CT, etc.) to see the leakage of the material that is in visible contrast with its surroundings.
  • medical visualization techniques e.g., MR, ultrasound, fluoroscopy, PET, CT, etc.
  • delivery characteristics of either a general nature (developing general procedural formats), a device specific nature (for different catheter designs and sealing system designs) or a patient specific nature (developing patient specific procedural formats) can be determined.
  • the format for a specific patient can be performed well in advance of the actual treatment, or can be performed immediately preceding the treatment, using an inert observable medium for observation.
  • a plan or strategy of treatment can be developed from the observed characteristics.
  • One method adopted was to construct a model of a simple twin-stent catheter design of which the principal novel feature was a pair of stents lying in the main axis of the catheter needle very near the distal tip.
  • Each stent consists of a short length of silicon or polymer tube mounted around the catheter core between the casing and the enlarged needle tip.
  • the stents are used so that one stent is positioned interior of the puncture and the other stent is positioned exterior of the puncture.
  • the two stents act in concert to apply pressure around the circumference of the puncture from both sides of the pia to form a seal round the periphery of the puncture. This seals the puncture against back leakage.
  • Compression of the twin stents by means of the reduction of the gap between the two stents on opposite sides of the puncture causes each stent to displace outwards, consequently adopting the form of a disc instead of a cylinder. If both stents or even a single flexible stent is on one side of the puncture, sufficient pressure against a flexible, elastic stent at an end of the stent distal from the puncture can assist in causing the end of the stent proximal to the puncture to press on the circumference of the puncture and even to distend outwardly in the middle of the stent to form a doughnut-like shape and assist in sealing the puncture further.
  • a narrow washer (of the same diameter as the casing and tip) may be used to separate the two stents causes them to distort identically.
  • the needle tip is preferably placed within the outer casing and is partially withdrawn.
  • the spring stiffness (resilience) then pushes and expands the rubber or rubber-like stents which in turn expand outwardly.
  • the stents when expanded do so equally and form the seal.
  • a flowable material is generally a liquid solution, but may also be a suspension, dispersion or emulsion that exhibits flowable characteristics similar to those of a liquid.
  • the method may comprise identifying a region of a patient to be viewed or treated; identifying a shaped volume between two distinct surfaces within the region; identifying a flow redirection mechanism to confine infusate within the shaped volume; and providing material from a material delivery device into the shaped volume to create a delivery volume between the two distinct surfaces containing at least delivered material.
  • the method may use an active response of the tissue to flow of infusate that is considered in restricting the flow to within said volume.
  • FIG. 1 shows a schematic of an assembled twin-stent catheter 100 in pre-insertion mode.
  • the catheter 100 elements 101 which is a position stabilizing element or plate; 103 which is a screw threading or other mechanical advancing system; 105 which is a guidance support element; 108 which are a pair of stents that are separated by spacer 107 and the insertion tip 109 of the catheter 100 .
  • FIG. 2 shows the component parts of a twin-stent catheter 200 comprising the guidance support element 202 , the position stabilizing element 205 , a pair of threaded advancing systems 207 208 , the catheter tip 214 , the two stents 212 and the spacer 210 between the stents 212 .
  • FIG. 3 shows the distal tip 304 of the twin-stent catheter 300 in pre-insertion mode.
  • the barrel 306 extends to the pointed end 314 of the catheter 300 where the twin or dual stents 312 are separated by the spacer 310 , which may also operate to close or diminish any penetration hole by being expansible.
  • FIG. 4 shows a schematic of the twin-stent catheter 400 in initial position piercing the pia 408 .
  • the forward stent 406 is shown along with the pointed tip 410 on the distal side of the pia 408 .
  • the proximal stent 405 is shown on the proximal side of the pia 408 along with the guidance support element 404 and the stabilizing support element 402 .
  • FIG. 5 shows a drawing of the contracted twin-stent catheter 500 gripping the pia 504 .
  • the two stents 508 are inflated to stabilize the catheter and seal the hole (not shown) from the puncture by the pointed tip 506 .
  • the guidance support element 501 and the stabilizing support element 502 are examples of the holes (not shown) from the puncture by the pointed tip 506 .
  • the various twin/dual stent catheters may be held firmly in this position by the locating jig (not shown or described) whereby the adjuster screw is then tightened so that the two stents distort to the extent that they firmly grip the pia between them, thus sealing the hole made in it by the entry of the catheter.
  • a threaded nut-and-screw arrangement allows for the manual adjustment of the compression of the stents and therefore the degree of distortion of the pair of stents.
  • a spring contained within the case may be used to return the stents to their original at-rest cylindrical form when the adjusting screw is slacked off.
  • the stents distort because the space available to them is reduced. It follows that the distance between the washer located between the two stents and the distal tip of the catheter needle is also reduced as the distortion is increased. The position of the casing of the catheter therefore needs to be slightly adjusted to maintain the washer at the level of the pia so that the stents precisely grip the pia between them as they complete their distortion.
  • a flowable material is generally a liquid solution, but may also be a suspension, dispersion or emulsion that exhibits flowable characteristics similar to those of a liquid.
  • the method may comprise identifying a region of a patient to be viewed or treated; identifying a shaped volume between two distinct surfaces within the region; identifying a flow redirection mechanism to confine infusate within the shaped volume; and providing material from a material delivery device into the shaped volume to create a delivery volume between the two distinct surfaces containing at least delivered material.
  • the method may use an active response of the tissue to flow of infusate that is considered in restricting the flow to within said volume.
  • the method may be practiced where a path of movement of the delivered material is confined or directed in flow by exploitation of backflow and redirection.
  • the backflow and redirection (as described herein) may be created by pneumatic and tensile forces provided by at least one of the delivered material, tensile forces of the two distinct surfaces, shape change of the delivery device and volume change of the delivery device.
  • FIG. 4 shows the distal tip of the catheter with the twin stents contracted to form the doughnut-like gasket elements that can seal the hole in the pia from two sides of the puncture.
  • FIG. 5 actually shows the contracted external stent from a twin stent catheter pair gripping the pia, creating a seal around the puncture.
  • an effective seal can be provided.
  • pneumatic pressure might be used to provide pressure and extend the area of coverage of the device component.
  • a lip, grip, tongue or other structural component may be used to keep the distal side of the stent or gasket restricted from sliding along the catheter while the expanding stent or gasket applies greater pressure against the pia puncture.
  • the medication will normally be observed to flow back up the resistant edge of the catheter towards the surface of the cortex and the pia.
  • the hole in the pia made by the catheter is now sealed by the twin stents the medication forms a bolus contained by the pia and then quickly disperses over the cortical surface, in the space between the cortical surface and the pia in the desired manner without any additional external intervention.
  • the variations in design can be observed to determine their effects on actual process events and results.
  • this catheter is to enable the introduction of a drug between the pia and the cortex or within the cortex while preventing back flow along the needle and past the pia.
  • the pia membrane is extremely delicate and vulnerable to physical damage, but is an effective physical barrier beyond which any introduced drug must consequently be placed. It is therefore generally necessary to pierce the pia membrane (and the other membranes outside it) with the catheter end in order to introduce the therapeutic drug.
  • the normal flow-path that is created when the drug is introduced under pressure is back along the path of the catheter needle and out through the hole cut through the pia by the needle. This back-flow phenomenon results in a partial failure to introduce the drug and difficulty in determining the amount of drug that has actually been introduced.
  • the parasol seal catheter can address this problem after the tip of the catheter will pierce the dura and pia membranes.
  • the catheter will ordinarily consist of concentric tubes, although parallel adjacent tubes or helixing tubes may also be used. In the specific design shown in FIG. X, there may be a space between the outer and inner tubes, located by internal spacing fins that will be used to generate slight suction.
  • the protruding length of the inner tube will be variable, adjustable or fixed. Drug delivery preferably will be affected through the inner tube, although this is a design choice.
  • the inner tube may have an area of reduced outside diameter near the piercing tip of the catheter in order to accommodate the folded ‘parasol.’
  • the parasol which displays a forward looking or rearward looking convex surface (preferably a sloped, curved, spherical or ellipsoidal surface) and an opposed rearward looking and forward looking opposed (respectively) concave surface (preferably a sloped, curved, spherical or ellipsoidal surface)
  • an inflatable or expansible balloon-type structure that would have the convex curved or sloped surfaces on both the forward looking and rearward looking sections of the balloon.
  • sloped is meant a not necessarily curved surface upon expansion of the balloon or parasol, but a shape that might be more pyramidal in geometry, with straight lines and edges.
  • the parasol shown in FIG. 11 is shown to consist of a cone of an extremely thin membrane, the rim of which may be very slightly reinforced.
  • the circumference of the truncated cone of the parasol membrane may be attached to the inner tube at the forward end of the parasol recess.
  • the piercing inner tube is then shown to be slightly withdrawn, collapsing the parasol back against the inside of the pia.
  • the parasol membrane now covers the gap between the pierced edge of the hole in the pia and the needle, the outer diameter of the parasol being significantly greater than that of the piercing needle.
  • Very gentle suction is now applied through the void within the outer tube, the reduced pressure drawing the dura and pia together and pulling the parasol membrane against the pia and into any gaps between the pia and the needle.
  • the parasol or balloon deployed on the first contacted side of the pia so that the seal is formed at a position on the proximal side of the pia, where the catheter first entered the tissue. This may be analogized to plugging a hole in the hull of a ship from inside the ship or outside the hull.
  • the material or drug is then introduced through the (preferred) inner needle or lumen while reduced fluid pressure (suction) is continuously maintained through the outer tube.
  • reduced fluid pressure suction
  • the normal back flow pattern means that the introduced drug will initially attempt to flow back along the outside of the needle to the surface of the cortex and the underside of the pia. However, where previously the drug would then leak out through the hole made in the pia by the piercing inner needle, the Parasol Seal Catheter would allow the drug to accumulate around the needle below the parasol, between the pia and the cortex. As the quantity of drug increases so this reservoir would spread outwards, bathing an increasing area of the surface of the cortex in the introduced drug.
  • the Single Rifle form consists of a simple cannula, the inner surface of the tube forming the cannula being rifled by means of a spiral projection or groove that runs down its internal length.
  • the rifling imparts a twist to the flow of the liquid, creating a greater degree of directional flow stability that continues once it passes the distal tip of the cannula and enters the brain.
  • This increased directional stability enables the flow to continue directly outwards from the cannula tip. This contrasts to the situation when a conventional un-rifled cannula is used, in which case the liquid normally reverses direction and flows back up the outside of the cannula.
  • an additional measure may be used, in the form of a Double Rifle cannula.
  • a Double Rifle cannula shares the interior spiral rifling typical of the Single Rifle in order to maximize the directional stability of the infusate flow, but has additional exterior rifling grooves along the exterior wall of the cannula.
  • saline solution is pumped along (up or down) the exterior rifling at a very slow rate and in a very small quantity. Any tendency for the infusate to flow back is defeated by the existing contrary or parallel flow of the saline solution, thus obliging or limiting the infusate to maintain its desired flow direction away from the distal tip into the brain.
  • the informing logic of the exterior rifling of the Double Rifle cannula recognises that infused liquids will find an easier pathway formed against an available hard surface. Thus back-flow occurs where the only available hard-surface path is back up the cannula towards the point of penetration.
  • the direction of flow is determined by the availability of a hard-surface path, not by any identification or primacy of “back” or “forward” direction.
  • the neutral saline solution infusate is preferably introduced along the cannula in a direction leading towards the interior of the brain. Any tendency of the drug being infused via the inside of the cannula to backflow will be discouraged by the (chemically neutral) liquid already flowing towards it down the external wall or filling the grooves.
  • the infused drug will consequently have lost its easier hard-surface path and will be more inclined to flow in the desired direction outward from the distal tip, encouraged by the enhanced directional stability imparted by the rifling on the internal surface of the cannula. It may be argued that the rifling on the external wall of the cannula is unnecessary, that the saline infusate will anyway take the hard-surface path towards the distal tip. However, the rifling assists in creating surface adhesion between the saline infusate and the cannula, in minimising any tendency of the saline solution itself to flow back and in assisting the directional tendency of the infused drug from the distal tip.
  • an Exterior Rifle cannula may be used. This consists of a cannula tube down which the infusate drug is pumped. Projecting from the distal tip of this tube is a solid needle, the outside of which is rifled. As the infusate emerges from the tube it takes the proffered hard-surface path down the outside of the rifled solid needle. When it reached the distal tip of the needle the liquid infusate cannot reverse back up the only existing hard-surface path, since this is blocked by the continuing flow of further infusate. Consequently the infusate forms a bolus, the direction imparted by the rifling causing it to locate slightly forward of the distal tip of the needle.
  • FIG. 14 Ventricle Circulation Catheter for Drug Delivery
  • This catheter design is to maintain the normal (e.g., cranial) pressure in a region of a patient while introducing material or drugs to the required region of the patient (e.g., cortex).
  • NP3 catheter will be introduced into the cortex, for example from the ventricle.
  • This embodiment of the catheter will be constructed from concentric tubes. Drug delivery under positive pressure will be through the inner tube. Negative or relatively reduced pneumatic (suction) pressure will be maintained in the gap between the inner tube and the outer tube. Fins, struts, (continuous or discontinuous) supports or splines running out along the longitudinal axis from the working end of the outer tube will maintain the relationship between the two tubes. The supports (e.g., fins) will also serve to create spaces between the inner tube and the membranes that it has pierced in order that the liquid can flow from the positive pressure at the piercing end of the inner tube back to the negative pressure at the end of the outer tube that remains outside the membrane pierced by the inner tube, as shown in FIG. 14 .
  • a pump connects the two tubes so that liquid circulates within the brain, coming out of the end of the piercing inner tube then back towards and into the open end of the outer tube. Within the catheter the liquid then passes up the outer tube, through the external pump and back down the piercing tube again.
  • the material or drug is introduced in a liquid form and metered at an external pump. Because liquid is being removed in direct proportion to its introduction, the increase in pressure is kept to a minimum, thus reducing the risk of therapy-induced trauma.
  • the length of the piercing inner tube projecting beyond the end of the fins can be adjusted or selected or modified (e.g., by initial design or in situ) according to the depth beyond the membrane that the drug should be delivered. Since the catheter makes use of backflow and even augments it by pneumatic pressure control (e.g., suction), the primary distribution will be around and along the penetrating length of the piercing inner tube.
  • pneumatic pressure control e.g., suction
  • the introduction of additional liquids will normally increase such pressure, restricting the volume of medication that can be introduced during a single procedure.
  • the intention of this catheter design is to minimise changes in (e.g., cerebral) pressure by balancing the pressure caused by the introduction of medication by the removal of an equal amount of (cerebral) fluid.
  • Medication is introduced through the tip of the catheter, resulting in positive pressure locally.
  • Flow patterns in this context are primarily back along the catheter needle and the puncture created by it. Introduced fluid under pressure will normally be expressed through the puncture in the pia, thus making metering of the medication inaccurate.
  • the vents at the base of the catheter needle allow the creation of negative pressure, thus encouraging the flow of medication from needle tip to needle base but reducing the risk of leakage through the hole in the pia. Near normal pressure is thus maintained within the cortex.
  • a metered medication reservoir will allow measurement of the dose delivered, even if it circulates for a period before being absorbed. Although some additional pressure is created by the addition of the medication, this will be kept to a minimum because the lack of leakage means that no excess dose needs to be delivered to allow for wastage. If zero pressure increase is necessary this could be achieved by the removal of an amount of cortical fluid equal to the volume of medication that is added. (In this case there should not be simple circulation of fluids.) The distance between needle tip and the vents is adjustable, thus controlling the depth to which medication is administered.
  • the present catheter model is probably larger than an operational version and has not been made to scale, but this is only an issue of scale.
  • the limited purpose of the model is to allow initial tests of the underlying principle of the design and to direct subsequent development of the design.
  • the model is constructed from stainless steel, which would not be the case for an operational version.
  • the prototype model has been made entirely by hand and therefore contains a level of inaccuracy and roughness which would not be the case in a more advanced operational prototype.
  • the slots might be cut by laser instead of with a hand saw.
  • a medication reservoir and one or two pressure gauges will need to be available.
  • a large scale simulation of the dura and pia with cortical fluid contained beneath them will need to be constructed, for example by using a vessel containing a slightly thickened liquid covered by saran wrap (cling film) that is in direct contact with the liquid it encloses.
  • the body of the catheter may consist of a long tube (a) with a shorter tube (b) attached at right angles near the top end.
  • a ‘stop’ ring (c) is attached to the lower extreme of the main body tube in order to limit the penetration of the catheter into the pia and soft tissue of the brain.
  • a smaller diameter tube protrudes (d) which has longitudinal vent slots cut in it through which the negative pressure will be created.
  • a short lateral tube is attached (b). This is the negative exit to which a flexible tube leading to the negative side of an external pump will be attached.
  • a lateral weld groove in the main body tube lying in the same axis, is a short section of tube containing a silicon grommet (e) that seals the main body chamber to prevent any loss of negative pressure within the body and to grip the catheter needle (f) in the required position.
  • Catheter needle The catheter needle (f) passes within the full length of the main body, centred by the vents at the lower end and the silicon seal at the top end. At the top end of the catheter needle are welded concentric larger tubes (g) to increase the diameter to one to which can be attached a tube leading to an external medication reservoir and from there to the positive pressure side of the external pump.
  • the length of catheter needle protruding from the vents at the lower end of the main body can be adjusted by grasping the top, large tube, end of the needle and pushing or pulling it firmly through the main tube against the grip of the silicon grommet. While the needle can be fully removed from the main body, repeated re-insertion will damage the silicon seal. Unless there is a specific problem that requires removal of the catheter needle from the main body it is therefore recommended to avoid doing so.
  • the inlet (positive pressure) tube on the catheter needle is connected to the external medication reservoir, which is in turn connected to the outlet of the external pump.
  • the outlet (negative pressure) tube (b) is connected to the inlet tube on the external pump.
  • the catheter needle (f), connecting tubes, reservoir and pump(s) should be filled with liquid and without air. The needle length is adjusted by pushing or pulling the needle through the main body of the catheter.
  • the catheter needle is pushed through the saran wrap barrier (pia) until the vent slots (d) also penetrate, the stop ring (c) resting gently against the barrier.
  • positive pressure is introduced by the introduction of ‘medication,’ balanced as closely as possible by negative pressure at the vents slots. Since the liquid to be circulated will have a certain viscosity, the pressure should only gradually be increased so that the flow is initiated before significant pressure is generated.
  • the catheter should be carefully rinsed after each test so that the fine vent holes do not become blocked.
  • FIG. 1 Catheter 100 Adjustment 101 Thread 103 Casing 105 Washer 107 Stents 108 Needle tip 109 FIG. 2 Casing 202 Adjuster 205 Thread 207 Spring 209 Catheter 200 Washer 210 Stents 212 Needle tip 214 FIG. 4 Catheter 400 Adjustment 402 Casing 404 Stent 405 Stent 406 Pia 408 Needle tip 410 FIG. 5 Catheter 500 Casing 501 Adjustment 502 Pia 504 Needle tip 506 Stents open 508 FIG. 10 Inflowing liquid 1001 Inner tube 1002 Outer tube 1004 Suction 1005 Parasol 1007 Piercing tube 1008 FIG. 11 Inner tube 1110 Piercing tube 1120 Parasol recess 1130 Parasol 1135 FIG.
  • the Putz assembly ensures delivery of the drug to the selected site by providing a barrier which prevents “backflow” or leakage of the drug.
  • the assembly includes a guide catheter having an inflatable balloon which is able to seal or occlude the tract created by the insertion of the guide catheter into the brain.
  • the guide catheter further includes a passageway which receives a delivery catheter through which the drug is administered to the selected site in the brain. This is distinct from the action of the present technology in which a shape is distorted and not inflated (that is there may be less than 10%, less than 5% and less than 25 down to 0%, change in volume of the present system, which is not inflation as performed by Putz).
  • the present system also operates to trap the delivered material between existing layers and not to block only backflow.
  • the inflation places outward pressure (radial pressure) against the edges of the hole itself, likely to propagate the tearing of the hole.
  • This is in contrast with the technology described herein where distortion or even inflation on opposed sides of the opening but not within the opening to any extent, would seal the hole around the edges by pressure on both sides of the hole confining the edges of the hole perpendicular to the surfaces of the tissue rather than radially within the hole.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
US11/434,080 2006-05-15 2006-05-15 Active delivery and flow redirection: novel devices and method of delivery of materials to patients Expired - Fee Related US7998128B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US11/434,080 US7998128B2 (en) 2006-05-15 2006-05-15 Active delivery and flow redirection: novel devices and method of delivery of materials to patients
PCT/US2007/011634 WO2007133776A2 (fr) 2006-05-15 2007-05-14 Administration active et réorientation de flux : nouveaux dispositifs et méthode d'administration de substances à des patients
US12/226,579 US20100030102A1 (en) 2006-05-15 2007-05-14 Active Delivery and Flow Redirections: Novel Devices and Method of Delivery of Materials to Patients

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/434,080 US7998128B2 (en) 2006-05-15 2006-05-15 Active delivery and flow redirection: novel devices and method of delivery of materials to patients

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/226,579 Continuation-In-Part US20100030102A1 (en) 2006-05-15 2007-05-14 Active Delivery and Flow Redirections: Novel Devices and Method of Delivery of Materials to Patients

Publications (2)

Publication Number Publication Date
US20070276340A1 US20070276340A1 (en) 2007-11-29
US7998128B2 true US7998128B2 (en) 2011-08-16

Family

ID=38694545

Family Applications (1)

Application Number Title Priority Date Filing Date
US11/434,080 Expired - Fee Related US7998128B2 (en) 2006-05-15 2006-05-15 Active delivery and flow redirection: novel devices and method of delivery of materials to patients

Country Status (2)

Country Link
US (1) US7998128B2 (fr)
WO (1) WO2007133776A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9668853B2 (en) 2011-07-06 2017-06-06 Taewoong Medical Co., Ltd. Stent for connecting adjacent tissues of organs
WO2019222441A1 (fr) 2018-05-16 2019-11-21 Voyager Therapeutics, Inc. Sérotypes de vaa pour l'administration de charge utile spécifique au cerveau
EP3632923A1 (fr) 2015-01-16 2020-04-08 Voyager Therapeutics, Inc. Polynucléotides de ciblage du système nerveux central

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0616411D0 (en) 2006-08-18 2006-09-27 Renishaw Plc Neurosurgical instruments
US7988674B2 (en) 2006-10-30 2011-08-02 Medtronic, Inc. Externally releasable body portal anchors and systems
US8480626B2 (en) 2007-11-30 2013-07-09 Medtronic, Inc. Infusion catheter assembly with reduced backflow
US9002076B2 (en) * 2008-04-15 2015-04-07 Medtronic, Inc. Method and apparatus for optimal trajectory planning
US8834446B2 (en) * 2008-06-12 2014-09-16 DePuy Synthes Products, LLC Pulsatile flux drug delivery
US8992568B2 (en) 2008-10-20 2015-03-31 Neil Duggal Systems and methods for cerebrospinal fluid repair
US8335552B2 (en) * 2009-03-20 2012-12-18 Medtronic, Inc. Method and apparatus for instrument placement
WO2011066340A1 (fr) 2009-11-24 2011-06-03 University Of Florida Research Foundation, Inc. Appareil et procédés permettant de bloquer les voies d'aiguilles et de canules
US20130035660A1 (en) 2011-08-01 2013-02-07 Alcyone Lifesciences, Inc. Multidirectional microfluidic drug delivery devices with conformable balloons
CN104582610B (zh) * 2012-07-24 2018-03-20 瑞尼斯豪公司 神经外科设备和方法
EP3868541A1 (fr) 2012-12-18 2021-08-25 Alcyone Lifesciences, Inc. Appareils et procédés permettant d'éviter un reflux dans un système de distribution
EP3010574B1 (fr) 2013-06-17 2019-12-18 Alcyone Lifesciences, Inc. Dispositifs de protection d'embouts de cathéters et fixations stéréotactiques pour microcathéters
WO2015017609A2 (fr) 2013-07-31 2015-02-05 Alcyone Lifesciences, Inc. Systèmes et procédés d'administration de médicament, de traitement et de surveillance
CN103700083B (zh) * 2013-12-26 2017-02-22 中国人民解放军广州军区武汉总医院 基于自适应模糊神经网络模型ct灌注图像智能融合方法
GB201404978D0 (en) 2014-03-20 2014-05-07 Renishaw Plc Neurosurgical apparatus
US10806396B2 (en) 2015-01-26 2020-10-20 Alcyone Lifesciences, Inc. Drug delivery methods with tracer
US10531882B2 (en) 2016-01-04 2020-01-14 Alcyone Lifesciences, Inc. Methods and devices for treating stroke
CN110152118A (zh) * 2018-01-16 2019-08-23 陆骊工 一种用于肿瘤药物注射防药物反流装置
CN110288693A (zh) * 2019-06-06 2019-09-27 昆明医科大学第二附属医院 一种颅内动脉瘤介入手术智能微导管塑形系统
CN111374740B (zh) * 2020-04-22 2021-10-08 重庆市江津区中心医院 一种房间隔穿刺术用增强现实辅助穿刺系统
US20250161627A1 (en) 2023-10-27 2025-05-22 Nowwell Flow Technology AS Catheter

Citations (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896816A (en) * 1971-05-03 1975-07-29 Martin Mattler Disposable catheter
US4807620A (en) 1987-05-22 1989-02-28 Advanced Interventional Systems, Inc. Apparatus for thermal angioplasty
US4824436A (en) 1985-04-09 1989-04-25 Harvey Wolinsky Method for the prevention of restenosis
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US4941874A (en) 1987-08-11 1990-07-17 Hoechst Aktiengesellschaft Device for the administration of implants
US4973304A (en) 1984-02-07 1990-11-27 National Research Development Corporation Device for sustained release of active substance
US5017566A (en) 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
US5082670A (en) 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US5087256A (en) 1990-01-12 1992-02-11 Metcal Inc. Thermal atherectomy device
US5106627A (en) 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US5120322A (en) 1990-06-13 1992-06-09 Lathrotec, Inc. Method and apparatus for treatment of fibrotic lesions
US5167625A (en) 1990-10-09 1992-12-01 Sarcos Group Multiple vesicle implantable drug delivery system
US5171217A (en) 1991-02-28 1992-12-15 Indiana University Foundation Method for delivery of smooth muscle cell inhibitors
US5195526A (en) * 1988-03-11 1993-03-23 Michelson Gary K Spinal marker needle
US5226902A (en) 1991-07-30 1993-07-13 University Of Utah Pulsatile drug delivery device using stimuli sensitive hydrogel
US5328456A (en) * 1990-11-13 1994-07-12 Nidek Co., Ltd. Irrigation and aspiration apparatus
US5487739A (en) 1987-11-17 1996-01-30 Brown University Research Foundation Implantable therapy systems and methods
US5514092A (en) 1994-08-08 1996-05-07 Schneider (Usa) Inc. Drug delivery and dilatation-drug delivery catheters in a rapid exchange configuration
US5569197A (en) 1994-12-21 1996-10-29 Schneider (Usa) Inc Drug delivery guidewire
US5571089A (en) 1993-06-30 1996-11-05 Cardiovascular Dynamics, Inc. Low profile perfusion catheter
US5573668A (en) 1990-10-30 1996-11-12 Minnesota Mining And Manufacturing Company Hydrophilic microporous membrane for drug delivery devices and method for preparing same
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5607418A (en) 1995-08-22 1997-03-04 Illinois Institute Of Technology Implantable drug delivery apparatus
US5697946A (en) * 1994-10-07 1997-12-16 Origin Medsystems, Inc. Method and apparatus for anchoring laparoscopic instruments
US5762926A (en) 1988-12-15 1998-06-09 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage of the central nervous system
US5843048A (en) 1996-08-06 1998-12-01 The Kendall Company Epidural catheter needle
US5865728A (en) * 1991-05-29 1999-02-02 Origin Medsystems, Inc. Method of using an endoscopic inflatable lifting apparatus to create an anatomic working space
US5964705A (en) 1997-08-22 1999-10-12 Image-Guided Drug Delivery System, Inc. MR-compatible medical devices
US6026316A (en) 1997-05-15 2000-02-15 Regents Of The University Of Minnesota Method and apparatus for use with MR imaging
US6059734A (en) * 1995-01-06 2000-05-09 Yoon; Inbae Methods of collecting tissue at obstructed anatomical sites
US6061587A (en) 1997-05-15 2000-05-09 Regents Of The University Of Minnesota Method and apparatus for use with MR imaging
US6263237B1 (en) * 1997-05-01 2001-07-17 Medtronic, Inc. Techniques for treating anxiety disorders by brain stimulation and drug infusion
US20020019623A1 (en) 1998-04-08 2002-02-14 Altman Peter A. Device and method to slow or stop the heart temporarily
US20020188167A1 (en) * 2001-06-06 2002-12-12 Anthony Viole Multilumen catheter for minimizing limb ischemia
US6506378B1 (en) 1998-12-16 2003-01-14 Arch Development Corporation Vesicular monoamine transporter gene therapy in Parkinson's disease
US20030014016A1 (en) * 2001-07-13 2003-01-16 Purdy Phillip D. Methods and apparatuses for navigating the subaracnhnoid space
US6537232B1 (en) 1997-05-15 2003-03-25 Regents Of The University Of Minnesota Intracranial pressure monitoring device and method for use in MR-guided drug delivery
US20030097116A1 (en) 2001-11-16 2003-05-22 Putz David A. Drug delivery catheter assembly with inflatable balloon
US6626902B1 (en) 2000-04-12 2003-09-30 University Of Virginia Patent Foundation Multi-probe system
US20030202990A1 (en) * 2000-06-14 2003-10-30 Allergan, Inc. Intracranial botulinum toxin therapy for focal epilepsy
US6663857B1 (en) 1991-08-13 2003-12-16 The Regents Of The University Of California In vivo gene transfer using implanted retroviral producer cells
US6749833B2 (en) 2001-05-25 2004-06-15 Bresagen Limited Design and planning system for improving the survival rate of injected structures
US20050085790A1 (en) * 2003-09-15 2005-04-21 James Guest Method and system for cellular transplantation
US6950699B1 (en) * 2001-12-12 2005-09-27 Brain Child Foundation Water content probe
US20070060973A1 (en) * 2005-09-12 2007-03-15 Nandor Ludvig Apparatus and method for monitoring and treatment of brain disorders

Patent Citations (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896816A (en) * 1971-05-03 1975-07-29 Martin Mattler Disposable catheter
US4973304A (en) 1984-02-07 1990-11-27 National Research Development Corporation Device for sustained release of active substance
US4824436A (en) 1985-04-09 1989-04-25 Harvey Wolinsky Method for the prevention of restenosis
US4807620A (en) 1987-05-22 1989-02-28 Advanced Interventional Systems, Inc. Apparatus for thermal angioplasty
US4941874A (en) 1987-08-11 1990-07-17 Hoechst Aktiengesellschaft Device for the administration of implants
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5487739A (en) 1987-11-17 1996-01-30 Brown University Research Foundation Implantable therapy systems and methods
US5106627A (en) 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US5017566A (en) 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
US5195526A (en) * 1988-03-11 1993-03-23 Michelson Gary K Spinal marker needle
US5762926A (en) 1988-12-15 1998-06-09 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage of the central nervous system
US5082670A (en) 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5087256A (en) 1990-01-12 1992-02-11 Metcal Inc. Thermal atherectomy device
US5120322A (en) 1990-06-13 1992-06-09 Lathrotec, Inc. Method and apparatus for treatment of fibrotic lesions
US5167625A (en) 1990-10-09 1992-12-01 Sarcos Group Multiple vesicle implantable drug delivery system
US5573668A (en) 1990-10-30 1996-11-12 Minnesota Mining And Manufacturing Company Hydrophilic microporous membrane for drug delivery devices and method for preparing same
US5328456A (en) * 1990-11-13 1994-07-12 Nidek Co., Ltd. Irrigation and aspiration apparatus
US5171217A (en) 1991-02-28 1992-12-15 Indiana University Foundation Method for delivery of smooth muscle cell inhibitors
US5865728A (en) * 1991-05-29 1999-02-02 Origin Medsystems, Inc. Method of using an endoscopic inflatable lifting apparatus to create an anatomic working space
US5226902A (en) 1991-07-30 1993-07-13 University Of Utah Pulsatile drug delivery device using stimuli sensitive hydrogel
US6663857B1 (en) 1991-08-13 2003-12-16 The Regents Of The University Of California In vivo gene transfer using implanted retroviral producer cells
US5571089A (en) 1993-06-30 1996-11-05 Cardiovascular Dynamics, Inc. Low profile perfusion catheter
US5514092A (en) 1994-08-08 1996-05-07 Schneider (Usa) Inc. Drug delivery and dilatation-drug delivery catheters in a rapid exchange configuration
US5697946A (en) * 1994-10-07 1997-12-16 Origin Medsystems, Inc. Method and apparatus for anchoring laparoscopic instruments
US5569197A (en) 1994-12-21 1996-10-29 Schneider (Usa) Inc Drug delivery guidewire
US6059734A (en) * 1995-01-06 2000-05-09 Yoon; Inbae Methods of collecting tissue at obstructed anatomical sites
US5607418A (en) 1995-08-22 1997-03-04 Illinois Institute Of Technology Implantable drug delivery apparatus
US5843048A (en) 1996-08-06 1998-12-01 The Kendall Company Epidural catheter needle
US6263237B1 (en) * 1997-05-01 2001-07-17 Medtronic, Inc. Techniques for treating anxiety disorders by brain stimulation and drug infusion
US6537232B1 (en) 1997-05-15 2003-03-25 Regents Of The University Of Minnesota Intracranial pressure monitoring device and method for use in MR-guided drug delivery
US6061587A (en) 1997-05-15 2000-05-09 Regents Of The University Of Minnesota Method and apparatus for use with MR imaging
US6026316A (en) 1997-05-15 2000-02-15 Regents Of The University Of Minnesota Method and apparatus for use with MR imaging
US5964705A (en) 1997-08-22 1999-10-12 Image-Guided Drug Delivery System, Inc. MR-compatible medical devices
US20020019623A1 (en) 1998-04-08 2002-02-14 Altman Peter A. Device and method to slow or stop the heart temporarily
US6506378B1 (en) 1998-12-16 2003-01-14 Arch Development Corporation Vesicular monoamine transporter gene therapy in Parkinson's disease
US6626902B1 (en) 2000-04-12 2003-09-30 University Of Virginia Patent Foundation Multi-probe system
US20030202990A1 (en) * 2000-06-14 2003-10-30 Allergan, Inc. Intracranial botulinum toxin therapy for focal epilepsy
US6749833B2 (en) 2001-05-25 2004-06-15 Bresagen Limited Design and planning system for improving the survival rate of injected structures
US20020188167A1 (en) * 2001-06-06 2002-12-12 Anthony Viole Multilumen catheter for minimizing limb ischemia
US20030014016A1 (en) * 2001-07-13 2003-01-16 Purdy Phillip D. Methods and apparatuses for navigating the subaracnhnoid space
US20030097116A1 (en) 2001-11-16 2003-05-22 Putz David A. Drug delivery catheter assembly with inflatable balloon
US6656152B2 (en) * 2001-11-16 2003-12-02 Ad-Tech Medical Instrument Corp. Drug delivery catheter assembly with inflatable balloon
US6950699B1 (en) * 2001-12-12 2005-09-27 Brain Child Foundation Water content probe
US20050085790A1 (en) * 2003-09-15 2005-04-21 James Guest Method and system for cellular transplantation
US20070060973A1 (en) * 2005-09-12 2007-03-15 Nandor Ludvig Apparatus and method for monitoring and treatment of brain disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Relux-free cannula for convection-enhanced high speed delivery of therapeutic agents" by Michal T. Krauze, et al. Journal of Neurosurgery, vol. 103, pp. 923-929, 2005.

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9668853B2 (en) 2011-07-06 2017-06-06 Taewoong Medical Co., Ltd. Stent for connecting adjacent tissues of organs
EP3632923A1 (fr) 2015-01-16 2020-04-08 Voyager Therapeutics, Inc. Polynucléotides de ciblage du système nerveux central
WO2019222441A1 (fr) 2018-05-16 2019-11-21 Voyager Therapeutics, Inc. Sérotypes de vaa pour l'administration de charge utile spécifique au cerveau

Also Published As

Publication number Publication date
WO2007133776A2 (fr) 2007-11-22
WO2007133776A9 (fr) 2008-01-10
WO2007133776B1 (fr) 2008-11-27
WO2007133776A3 (fr) 2008-10-02
US20070276340A1 (en) 2007-11-29

Similar Documents

Publication Publication Date Title
US7998128B2 (en) Active delivery and flow redirection: novel devices and method of delivery of materials to patients
US20100030102A1 (en) Active Delivery and Flow Redirections: Novel Devices and Method of Delivery of Materials to Patients
US11241526B2 (en) Method and system for enhanced imaging visualization of deep brain anatomy using infusion
US11833050B2 (en) Modulated ultra-sound compatible artificial cranial prosthesis
US20240115807A1 (en) Systems and Methods for Pressure-Facilitated Therapeutic Agent Delivery
EP1928557B1 (fr) Canule resistant au reflux et systeme d'administration chronique d'agents therapeutique active par convection
Raghavan et al. Convection-enhanced delivery of therapeutics for brain disease, and its optimization
US6061587A (en) Method and apparatus for use with MR imaging
US6026316A (en) Method and apparatus for use with MR imaging
US7505807B1 (en) Magnetic resonance apparatus for use with active electrode and drug deliver catheter
US20200375745A1 (en) Ultra-sound compatible artificial cranial prosthesis with customized platforms
US20120172838A1 (en) Systems and Methods for Delivering Drugs to Selected Locations Within the Body
JPS63500220A (ja) 人間の脳室系にカテーテルを案内するための装置
JP2003520080A (ja) 抗反跳カテーテル
WO1998052064A1 (fr) Procede et appareil d'administration ciblee de medicament a un patient, mettant en oeuvre une imagerie par resonance magnetique
WO2001085027A2 (fr) Procede et appareil destines a etre utilises avec une electrode active et un catheter d'administration de medicaments
US9757543B2 (en) Delivery of materials into margins of tissue cavities
JPH11285533A (ja) 多目的チューブ
Naidoo et al. Convection-Enhanced Drug Delivery in the Central Nervous System
RU2765846C1 (ru) Способ изолированной левосторонней долевой умбилико-кавальной перфузии печени в эксперименте

Legal Events

Date Code Title Description
AS Assignment

Owner name: THERATAXIS, LLC, MARYLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:POSTON, DAVID;RAGHAVAN, RAGHU;BRADY, MARTIN L.;REEL/FRAME:017989/0619;SIGNING DATES FROM 20060516 TO 20060522

Owner name: THERATAXIS, LLC, MARYLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:POSTON, DAVID;RAGHAVAN, RAGHU;BRADY, MARTIN L.;SIGNING DATES FROM 20060516 TO 20060522;REEL/FRAME:017989/0619

ZAAA Notice of allowance and fees due

Free format text: ORIGINAL CODE: NOA

ZAAB Notice of allowance mailed

Free format text: ORIGINAL CODE: MN/=.

STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2552); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Year of fee payment: 8

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20230816